Published in final edited form as:

Curr Opin Neurol. 2018 April ; 31(2): 126–133. doi:10.1097/WCO.0000000000000537.

Behavioral and Neuroanatomical Approaches in Models of Neurodevelopmental Disorders: Opportunities for Translation

Jill L Silverman¹ and Jacob Ellegood²

¹University of California, Davis, MIND Institute, School of Medicine, Sacramento, CA, USA

²Mouse Imaging Centre, The Hospital for Sick Children, Toronto, Canada

Abstract

Purpose of review—This review highlights the invaluable contribution of *in vivo* rodent models in dissecting the underlying neurobiology for numerous neurodevelopmental disorders. Currently, models are routinely generated with precision genomics and characterized for research on neurodevelopmental disorders. In order to impact translation, outcome measures that are translationally relevant are essential. This review emphasizes the importance of applicable, accurate neurobehavioral and anatomical analyses.

Recent findings—Numerous well-validated assays for testing alterations across behavioral domains with sensitivity and throughput have become important tools for studying the effects of genetic mutations on neurodevelopment. Recent work has highlighted relationships and links between behavioral outcomes and various anatomical metrics from neuroimaging via magnetic resonance. These readouts are biological markers and outcome measures for translational research and will have important roles for genetic or pharmacologic intervention strategies.

Summary—Combinatorial approaches that leverage translationally relevant behavior and neuroanatomy can be used to develop a platform for assessment of cutting edge preclinical models. Reliable, robust behavioral phenotypes in preclinical model systems, with clustering of brain pathology will lead to well-informed, precise biochemical mechanistic hypotheses. Ultimately, these steadfast workhorse techniques will accelerate the progress of developing and testing targeted treatments for multiple neurodevelopmental disorders.

Keywords

Mouse models; behavior; autism; brain; development; genetics; neurodevelopmental disorder; translation; anatomy

Introduction

Neurodevelopmental disorders (NDDs) are a broad, diverse group neuro-behavioral disorders defined by significant impairments in one or more domains of functioning (e.g.,

Correspondence should be addressed to: Jill L Silverman, Ph.D., MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, 4625 2nd Avenue, Sacramento, CA 95817, jsilverman@ucdavis.edu.

Conflicts of Interest

None

social interactions, cognition, language, motor behaviors). NDDs are prevalent and pervasive lifelong conditions. Deficits can include delays in achieving outcomes and impaired skills or the presentation of atypical behaviors. Although cures (e.g., gene therapy) are not imminent, recent innovations in delivery methods associated with gene products and targeted pharmaceuticals, when combined with evidence-based behavioral interventions, have reinvigorated basic and clinical research. The diagnostic criteria for NDDs, outlined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM5), are a group of neurodevelopmental disorders of unknown albeit numerous etiologies with no biological markers. Thus, a diagnosis is defined exclusively by *behavioral* criteria in the distinct domains. The most classic example is intellectual disability (ID), which is diagnosed by deficits in both intellectual and adaptive functioning relative to peers of the same age, sex and socioeconomic group. In addition to the features essential to a diagnosis of ID, challenging behaviors are frequently observed, often resulting from limitations in communicative and behavioral regulation abilities. Although the presence of challenging behaviors are not a part of the ID diagnosis, these behavioral deficits may impede the process of the appropriate ID diagnosis and course of intervention [1].

Autism spectrum disorder (ASD) is another prominent NDD diagnosed by 1) persistent impairments in reciprocal social interaction and deficits in social communication across multiple contexts and 2) repetitive behaviors, with highly fixated, restricted interests and behavioral inflexibility. DSM5 diagnoses include a broader definition of the ASD phenotype than earlier versions to better reflect the current consensus that the causes and clinical presentations of ASD are highly heterogeneous. ASD and Attention-Deficit/Hyperactivity Disorder (ADHD) are frequently co-occurring [2–4]. ADHD is characterized by persistent problems in attention and/or excessive motor restlessness and/or impulsivity that significantly interfere with functioning [5]. Impulsivity also refers to a lack of reflection in the decision-making process. Other NDDs fall into classes of communication or motor disorders, both of which are also heterogeneous. Communication disorders are diagnosed by one or more deficiencies in a wide variety of subdomains such as competence in phonology, morphology, syntax and pragmatics and may adversely affect any or all of these subdomains. Motor disorders are defined by significant delays to reach developmental motor milestones and/or persistent and unusual patterns of typical motor abilities that cause detrimental impact [5, 6].

Cutting-edge genetics fast forwards translational science

Stratifying patient phenotypic subgroups and focusing on genetically identifiable populations of individuals with NDDs is a main focus of neurological research. With the advent of next generation sequencing techniques, numerous genetic factors have been shown to confer risk for ASD and ID, with > 100 genes implicated in syndromic ASD cases [7–11] and over 700 genes identified across studies of X-linked, autosomal-dominant and autosomal-recessive ID, which can be used for the molecular diagnosis of ID and ASD [12–14]. Recently, whole exome and targeted sequencing approaches have further clarified the role of 49 different genes as greater than mere “candidate ASD genes,” but mid- to high-confidence genes [7, 15–17]. This past year, 8 novel precision medicine driven mouse models with mutations in two of the highest confidence genes, chromatin helicase domain 8

(*Chd8*) and AT-rich interactive domain 1B (*Arid1b*) debuted for behavioral, cellular, anatomical and molecular characterization studies [18–25]. As our knowledge of genes involved in NDDs, in particular ASD and ID, expands and the number of genes we identify increases, common pathways are emerging. Mechanistically, gene products of *de novo* mutations show strong enrichment for chromatin modifiers and transcriptional regulators (e.g., *CHD8*, *ARID1B*), embryonically expressed genes (e.g., *TBR1*, *DYRK1A*, *PTEN*), cellular signaling pathways (MAPK and Rho-GTPase) and are highly expressed in the postsynaptic density (e.g., *GRIN2B*, *GABRB3*, *SHANK3*). Networks constructed using these high-confidence risk genes reveal converging functional pathways in ASD and ID [11, 14, 26, 27].

Behavioral approaches in preclinical mouse models

Basic research into the above common underlying mechanisms of pathology to develop targeted treatment options first requires well-controlled *in vivo* studies in model organisms with a high degree of genetic conservation relative to humans. To date, the most useful models with high construct validity have been mouse models [28, 29]. Although forging definitive links between genetic alterations and complex behavioral impairments (i.e., face validity) is challenging, numerous behavioral assays relevant to the diagnostic domains of ASD, ID, ADHD and motor disorders provide researchers the opportunity to gain insight into how specific genetic mutations impact behavioral features. For one example of complex behavioral assessments, in ASD candidate gene models, social communication deficits can be tested using standard and innovative methods for quantifying behavior relevant to social communication [30–32]. Examples of assays that measure social communication include three-chambered approach, reciprocal dyad interactions, social recognition, social place preference, and ultrasonic vocalizations (USVs). Other assays relevant to DSM5 diagnostic criteria that quantify repetitive behavior and activity, relevant to numerous other NDDs, have revealed high levels of repetitive self-grooming [33–37], circling [38], jumping [39–41], back flipping [42, 43] and/or overall hyperactivity [44–46] in a broad variety of preclinical models. Insistence on sameness and lack of cognitive flexibility in NDDs has been modeled in several rodent models using a few different assays [47, 48]. Below, we highlight the breadth of examinations currently available in one behavioral domain, social behavior, that are utilized for identifying face validity (deficits in social communication) in construct valid genetic models.

Toward beneficial and comprehensive social behavioral phenotyping

Three-chambered approach is an automated and widely used assay that compares time that the subject mouse spends with a novel mouse versus time spent with a non-social inanimate object [49]. A more fine-grained level of detail is collected during the naturalistic reciprocal dyad interactions, where two unfamiliar subjects are placed together in a clean, empty test arena. Interactions are usually examined between sex- and age-matched juveniles and quantified parameters are from a rich history of the established literature [35, 50, 51]. These dyad interactions can also be quantified during male–female social interactions. USV calls, emitted by the sexually motivated male, can also be assessed during these tasks to provide two outcome measures of sociability. USVs are also emitted by rodent pups when separated

from their mothers and littermates and reductions in number of neonatal USV emissions have been reported in numerous ASD mouse models [35, 52–55]. Social recognition involves social memory and is commonly examined in rodents through a few different procedures that utilize the innate preference of adult rodents to spend more time with novel over familiar conspecifics. Dysregulation of the oxytocin system has been shown to be relevant for this component of social behavior [56] [57–59] [60]. Social conditioned place preference measures a component of social behavior alongside motivational components. Social place preference arenas pair one of two unique contexts with social interactions for a fixed number of conditioning sessions, during which wildtype control mice develop a place preference to the context associated with social interactions. Given the diversity of social behaviors (e.g., parental investment, mating, cooperation), this task is modifiable to measure motivation for subtypes of social reward and social behavior in models of NDDs [61]. However, one significant challenge to preclinical assays that quantify social behavior is the inability to lesion a brain region and eliminate all social behavior or pharmacologically validate and manipulate the behavior with positive control compounds, as behavioral scientists have been able to for other sophisticated behaviors (e.g., anxiety and benzodiazepines).

Social deficits in genetic mouse models of ASD across mechanisms of action have been reported but with an inconsistency of findings. Deficits in the social behavioral domain have been mild in some cases [62] or in other cases did not fully recapitulate across laboratory environments [63–67]. For a core pillar behavioral domain in ASD diagnosis, this re-emphasizes the need to conduct comprehensive, meticulous and more fine-grained analyses of complex behavioral tasks. Opportunities for the improvement of preclinical research in social behavior include applauding reports that fail to find a social deficit in a genetic mouse model of ASD. In the long run, the NDDs field would benefit from this cautionary approach before labeling a new mouse tool an “autism mouse” based on a mere single of these subtype(s) of behavioral findings that has not been reproduced either intra-or inter laboratory environments.

Key points from our laboratories, which have been successful with reproducibility efforts include a recommendation of using a minimum of two assays in each behavioral domain before making strong conclusions on social or cognitive behavioral phenotypes [68]. This point is especially salient for the social behavioral domain. Sociability is sophisticated and nuanced, much like complex executive learning functions. Moreover, there are numerous components of social behavior for a wide variety of functional outcomes including motivation, learning, dominance, thriving, maternal behavior and sex. Second, and importantly, is that methods employed for behavioral phenotyping of clinically relevant traits are riddled with nuance and should be conducted exclusively by trained technicians with demonstrated proficiency. Finally, to have the utmost translational value, behavioral phenotyping assays should be blinded, unbiased, and highly powered and appropriate age and sex-matched, littermate controls, in both males and females ($n = 15\text{--}20$ per genotype/sex for 2 independent cohorts) to assess behavioral abnormalities, analogous to observed in clinical populations. Other relevant biological variables such as breeding scheme, genetic background, enrichment in home cages and circadian rhythm/time of day should be carefully controlled, adequately considered, and described in severe detail in the methods text. The

importance of procedural and environmental differences often complicates direct comparisons of phenotypic data, however these points are not insurmountable [69, 70]. We and others have reported intra- and inter-laboratory, across time-zones, continents, and seasons replications in mouse models of NDDs [34, 35, 41, 54, 71–73].

Innovative outcome measures for cognition in NDDs

Until recently, cognitive tests for measuring learning and memory in animal models were underdeveloped in complexity, and with most commonly used tests employing rely on rudimentary stimuli and procedures. Most learning tasks are simplistic mazes and/or footshock-based paradigms. This uncritical use of behavioral paradigms may account for the low predictability of mouse models in psychiatric disorders. Newer assays of cognitive abilities for ASD, ID and ADHD include computerized assessments of simple learning, higher order cognitive flexibility, and attention and impulsivity, which are more ideal because they are automated and avoid investigator interference that can have enormous influence on behavioral effects. Automation in preclinical assays is also more analogous to increasingly automated clinical testing for NDDs (e.g., NIH toolbox), and is able to measure multiple domains of cognitive abilities and build upon previously learned rules. Automated touchscreen technology has been employed for tasks of visual discrimination and reversal to identify affected circuits in models with genetic mutations associated with ASD and ID [33, 74].

Considerations for complex behavioral phenotypes

For many of these complex behavioral assays outlined above, the ultimate goal is to identify disease-relevant endpoints that are robust, reliable, and reproducible, and that can be employed to evaluate potential novel therapeutic agents. The impact of a competing or confounding behavior on the behavioral endpoints listed above cannot be understated. For example, mutations can cause physical impairments that limit a subject's ability to perform a task. Genetic mutations relevant to ASD and ID that caused physical defects (e.g., smaller body weights) include the most common copy number variant in ASD, 16p11.2 deletions [38]. Motor defects in ASD models including hypo- [33, 34] and hyper-locomotion [44–46, 75–77] can also have consequences on the behavioral outcome of interest by competing or preventing the subject from engaging in the tasks of core symptomology testing. Just as it is important to understand the limitations of a behavioral task itself, it is important to investigate, acknowledge, and report the limitations of the rodent model being tested so as not to be shortsighted in the interpretations and applications of the data.

Neuroanatomical approaches in preclinical model systems

In conjunction to behaviorally relevant outcome measures, the search for biomarkers of NDDs has grown and heavily relied upon visualizing the brain in an effort to understand the neurodevelopmental differences in preclinical genetic models and to determine if those neuroanatomical alterations can be reversed or corrected [78, 79]. Neuroanatomical indices of pathology in preclinical models of NDDs have successfully identified phenotypes with cellular resolution, using techniques such as histology [80, 81], two photon microscopy [79],

and electron microscopy [82]. Mesoscopic resolution can be obtained with computed tomography (CT) [83, 84], positron emission tomography (PET) [85], and magnetic resonance imaging (MRI) [86, 87]. While the benefits of examining the brain at the cellular resolution are self-evident, such as visualization of processes and/or counting of the cell numbers, the lack of whole brain coverage often makes these techniques less than idyllic for NDDs, for which the behavior dysfunction is unlikely to be the result of a single localized brain region, highlighted by numerous clinical imaging studies in ASD, Fragile X and Prader-Willi syndromes [88–97].

MRI focused neuroanatomical phenotyping

The ability of MRI-based techniques to encompass multiple brain regions and circuits in a single study is highly advantageous to illustrate causal insults resulting of genetic mutations in a developed, living system. This comprehensive level of whole brain data collection provides a unique opportunity for neurodevelopmental research. Moreover, once methodologies are in place and optimized, MRI provides large datasets with efficiency, throughput and sensitivity [98]. Over the past decade, our collaborative laboratories have shown that most mouse models exhibiting behavioral phenotypes also have prominent detectable neuroanatomical phenotypes [55, 99–102]. The non-invasive nature of MRI also means that it can be performed repeatedly to track disease progression and loss of skills and/or symptom onset (or regression by reversals of brain phenotypes), extremely beneficial to neurodevelopmental research [103]. A broad variety of imaging sequences can be used to look at differential components of neurodevelopment. For example, diffusion tensor imaging (DTI) infers differences in the tissue microstructure throughout the brain and is extremely sensitive to differences in the white matter [104]. Preclinical studies using unbiased MRI in mouse models of NDDs have allowed for rapid whole brain phenotyping that alludes to future mechanistic hypothesis focused research with the aforementioned cellular resolution techniques. Because of this necessity in the genetic mouse model field, MRI assessments of the brain in NDDs have become a staple of the diagnostic battery used to comprehensively phenotype novel mouse models of NDDs.

With over 700 genes implicated in NDDs and greater than 250 mouse models generated to study ASD alone [106, 107], the demand is pronounced for high-throughput, quality, consistent, optimized and informative MRI scans. Our laboratory group at the Mouse Imaging Centre (MICE) has pioneered this advanced platform of mouse imaging and developed techniques to scan up to 16 mice in a single MRI session [86, 87], which has helped to maintain and scan the consistent stream of NDD relevant mouse models. Additional improvements to MRI systems such as higher fields or cryogen-cooled coils will help to enhance both the image quality and throughput even further in the near future [78].

Moving forward the most relevant and informative studies are going to be multi-modal combinations of several techniques including genomic analysis, behavioral phenotyping, global physiological outputs and neuroanatomical imaging.

Multi-modal phenotyping in next generation genetic mouse models

Advances in next generation genomic technology have greatly improved diagnostic capabilities for NDDs and have discovered consistent mutations across the heterogeneity, vigorously contributing to the growing preclinical models of NDDs pool. These studies have identified genes that regulate large gene networks, which end up regulating and affecting numerous postulated mechanisms of action including synaptic development, neuronal function, modulation of transcription process, chromatin remodeling, calcium signaling, and cellular signaling pathways. One example from whole exome sequences clarified the role of the chromodomain helicase DNA binding protein-8 (*CHD8*), with over 15 various mutations in this single gene confirmed to contribute to ASD [108–111].

Now, as the genetic models become available, our group has paved the way for a focused effort to comprehensively define the anatomical phenotype in an unbiased, hypothesis-generating effort that will contrast and compare differences across these models [99]. In collaboration with prominent behavioral scientists, we have spearheaded an effort to correlate neuroanatomical differences with behavioral metrics, which allows for powerful inferences and biochemical hypotheses to be pursued for any given study. In fact, showing direct relationships and links amongst behavior and any of our numerous MRI readouts (e.g., regional volume, DTI, cortical thickness) can be used as biological markers, outcome measures, and may define targets for genetic or pharmacologic intervention.

Recently, we jointly applied behavioral and neuroanatomical phenotyping on the *Chd8*^{+/-}*del5* model of *CHD8* mutation in ASD. We observed embryonic lethality in the homozygous subjects and global macrocephaly, cognitive behavioral deficits, cortical cytoarchitecture anomalies and atypical neurogenesis. Cognitive behavioral deficits were observed in two standard assays of learning and memory, the novel object recognition task and contextual fear conditioning. Since the behavioral and structural MRI analyses were performed in the same subject cohort, detected increases in absolute volume of the cortex, hippocampus, and amygdala were correlated with deficits (i.e., reduced freezing) in fear conditioning [19]. These additional correlations provide two complimentary clinically relevant outcome measures, which are desperately in demand for pharmaceutical development in NDDs. Other advantages of cross model phenotyping are to highlight brain regions or behavioral domains of interest and decipher previously unknown underlying neural networks. Our efforts of combining behavior with neuroanatomy will aid stratification efforts for NDDs, which will ultimately lead to an increased diagnostic specificity and streamlined therapeutic development.

Summary and Conclusions

Recent advances in neuroscience have fostered a shift in thinking as to how various clinical disorders and behaviors are mediated, with evidence pointing to subtle alterations across multiple brain regions, neurotransmitter systems, and synaptic processes that converge as neural circuits. While it is tempting to proceed with technological advances that allow us to examine and manipulate single cells, for neurodevelopmental disorders, a systems level approach is necessary and will be heavily relied upon for therapeutic development strategies.

As the number of sophisticated tools increases, we must not forget that there is no replacement for behavioral and neuroanatomical outcomes, the clinically relevant tools that continue to drive translational research forward.

Acknowledgments

We would like to acknowledge Ms. Liz Berg and Ms. Nycole Copping for their editorial support and for reading drafts of this piece throughout its assembly.

Financial support and sponsorship

We thank the MIND Institute, the NIH (R01NS097808), the Canadian Institute for Health Research and the Ontario Brain Institute.

Literature Cited

- McDuffie A, Abbeduto L, Lewis P, Kover S, Kim JS, Weber A, Brown WT. Autism spectrum disorder in children and adolescents with fragile x syndrome: Within-syndrome differences and age-related changes. *Am J Intellect Dev Disabil*. 2010; 115(4):307–326. [PubMed: 20567604]
- Antshel KM, Zhang-James Y, Faraone SV. The comorbidity of adhd and autism spectrum disorder. *Expert Rev Neurother*. 2013; 13(10):1117–1128. [PubMed: 24117274]
- Zablotsky B, Bramlett MD, Blumberg SJ. The co-occurrence of autism spectrum disorder in children with adhd. *J Atten Disord*. 2017 1087054717713638.
- Houghton R, Ong RC, Bolognani F. Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the united states. *Autism research : official journal of the International Society for Autism Research*. 2017
- Association, AP. Diagnostic and statistical manual of mental disorders: Dsm-5. American Psychiatric Association; Washington, D.C: 2013.
- Hales, RE., Yudofsky, SC., Roberts, LW. American Psychiatric Publishing. The american psychiatric publishing textbook of psychiatry. American Psychiatric Publishing; Washington, DC: 2014.
- Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, Stessman HA, Witherspoon KT, Vives L, Patterson KE, Smith JD, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature*. 2014; 515(7526):216–221. [PubMed: 25363768]
- Abrahams BS, Geschwind DH. Advances in autism genetics: On the threshold of a new neurobiology. *Nat Rev Genet*. 2008; 9(5):341–355. [PubMed: 18414403]
- Geschwind DH. Genetics of autism spectrum disorders. *Trends Cogn Sci*. 2011; 15(9):409–416. [PubMed: 21855394]
- Huguet, G., Benabou, M., Bourgeron, T. The genetics of autism spectrum disorders. In: Sassone-Corsi, P., Christen, Y., editors. A time for metabolism and hormones. Cham (CH): 2016. p. 101-129.
- Krumm N, O'Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neuroscience. *Trends Neurosci*. 2014; 37(2):95–105. [PubMed: 24387789]
- Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BW, Willemsen MH, Kwint M, Janssen IM, Hoischen A, Schenck A, Leach R, et al. Genome sequencing identifies major causes of severe intellectual disability. *Nature*. 2014; 511(7509):344–347. [PubMed: 24896178]
- Kaufman L, Ayub M, Vincent JB. The genetic basis of non-syndromic intellectual disability: A review. *J Neurodev Disord*. 2010; 2(4):182–209. [PubMed: 21124998]
- *14. Vissers LE, Gilissen C, Veltman JA. Genetic studies in intellectual disability and related disorders. *Nat Rev Genet*. 2016; 17(1):9–18. [PubMed: 26503795] A comprehensive review of innovative genetics technologies that have revealed mutations that cause hundreds of forms of intellectual disability.
- O'Roak BJ, State MW. Autism genetics: Strategies, challenges, and opportunities. *Autism research : official journal of the International Society for Autism Research*. 2008; 1(1):4–17. [PubMed: 19360646]

16. O'Roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, Vives L, Baker C, Hiatt JB, Nickerson DA, Bernier R, et al. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. *Nat Commun.* 2014; 5(5595)
17. De Rubeis S, He X, Goldberg AP, Poultnery CS, Samocha K, Cicek AE, Kou Y, Liu L, Fromer M, Walker S, Singh T, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature.* 2014; 515(7526):209–215. [PubMed: 25363760]
18. Durak O, Gao F, Kaeser-Woo YJ, Rueda R, Martorell AJ, Nott A, Liu CY, Watson LA, Tsai LH. Chd8 mediates cortical neurogenesis via transcriptional regulation of cell cycle and wnt signaling. *Nature neuroscience.* 2016; 19(11):1477–1488. [PubMed: 27694995]
- *19. Gompers AL, Su-Feher L, Ellegood J, Copping NA, Riyadh MA, Stradleigh TW, Pride MC, Schaffler MD, Wade AA, Catta-Preta R, Zdilar I, et al. Germline chd8 haploinsufficiency alters brain development in mouse. *Nature neuroscience.* 2017; 20(8):1062–1073. [PubMed: 28671691] Whole exome sequencing showed that over 15 various mutations of the CHD8 gene contributed to autism. This article was one of the first mouse models generated with *Chd8* mutations and discovered behavioral deficits were highly correlated with anatomical phenotypes.
20. Katayama Y, Nishiyama M, Shoji H, Ohkawa Y, Kawamura A, Sato T, Suyama M, Takumi T, Miyakawa T, Nakayama KI. Chd8 haploinsufficiency results in autistic-like phenotypes in mice. *Nature.* 2016; 537(7622):675–679. [PubMed: 27602517]
21. Platt RJ, Zhou Y, Slaymaker IM, Shetty AS, Weisbach NR, Kim JA, Sharma J, Desai M, Sood S, Kempton HR, Crabtree GR, et al. Chd8 mutation leads to autistic-like behaviors and impaired striatal circuits. *Cell Rep.* 2017; 19(2):335–350. [PubMed: 28402856]
22. Wang P, Mokhtari R, Pedrosa E, Kirschenbaum M, Bayrak C, Zheng D, Lachman HM. Crispr/cas9-mediated heterozygous knockout of the autism gene chd8 and characterization of its transcriptional networks in cerebral organoids derived from ips cells. *Molecular autism.* 2017; 8:11. [PubMed: 28321286]
23. Celen C, Chuang JC, Luo X, Nijem N, Walker AK, Chen F, Zhang S, Chung AS, Nguyen LH, Nassour I, Budhipramono A, et al. Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment. *Elife.* 2017; 6
24. Jung EM, Moffat JJ, Liu J, Dravid SM, Gurumurthy CB, Kim WY. Arid1b haploinsufficiency disrupts cortical interneuron development and mouse behavior. *Nature neuroscience.* 2017; 20(12):1694–1707. [PubMed: 29184203]
25. Shibutani M, Horii T, Shoji H, Morita S, Kimura M, Terawaki N, Miyakawa T, Hatada I. Arid1b haploinsufficiency causes abnormal brain gene expression and autism-related behaviors in mice. *Int J Mol Sci.* 2017; 18(9)
- *26. Vorstman JAS, Parr JR, Moreno-De-Luca D, Anney RJL, Nurnberger JI Jr, Hallmayer JF. Autism genetics: Opportunities and challenges for clinical translation. *Nat Rev Genet.* 2017; 18(6):362–376. [PubMed: 28260791] A comprehensive review of the novel genetic studies that have revealed the involvement of hundreds of gene variants in autism. This review highlights that while the genetics are complex there is much convergence in basic underlying biology.
27. Lasalle JM. Autism genes keep turning up chromatin. *OA Autism.* 2013; 1(2):14. [PubMed: 24404383]
28. Crawley JN. What's wrong with my mouse?: Behavioral phenotyping of transgenic and knockout mice. Wiley-Interscience; Hoboken, NJ: 2007.
29. Crawley JN. Behavioral phenotyping strategies for mutant mice. *Neuron.* 2008; 57(6):809–818. [PubMed: 18367082]
- *30. Sukoff Rizzo SJ, Silverman JL. Methodological considerations for optimizing and validating behavioral assays. *Current protocols in mouse biology.* 2016; 6(4):364–379. [PubMed: 27906464] For many of these complex behavioral assays outlined above, the ultimate goal is to identify disease-relevant endpoints that are robust, reliable, and reproducible, and that can be employed to evaluate potential novel therapeutic agents.
31. Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. *Nat Rev Neurosci.* 2010; 11(7):490–502. [PubMed: 20559336]

32. Kazdoba TM, Leach PT, Yang M, Silverman JL, Solomon M, Crawley JN. Translational mouse models of autism: Advancing toward pharmacological therapeutics. *Current topics in behavioral neurosciences*. 2016; 28:1–52. [PubMed: 27305922]
- *33. Copping NA, Berg EL, Foley GM, Schaffler MD, Onaga BL, Buscher N, Silverman JL, Yang M. Touchscreen learning deficits and normal social approach behavior in the shank3b model of phelan-mcdermid syndrome and autism. *Neuroscience*. 2017; 345:155–165. [PubMed: 27189882] Cognitive abilities for can be tested by computerized assessments. This is the debut article that illustrated automation in preclinical assays that is analogous to the NIH toolbox and identified deficits in a mouse model with genetic mutations associated with ASD and ID.
34. Dhamne SC, Silverman JL, Super CE, Lammers SHT, Hameed MQ, Modi ME, Copping NA, Pride MC, Smith DG, Rotenberg A, Crawley JN, et al. Replicable in vivo physiological and behavioral phenotypes of the shank3b null mutant mouse model of autism. *Molecular autism*. 2017; 8:26. [PubMed: 28638591]
35. Yang M, Bozdagi O, Scattoni ML, Wöhr M, Roulet FI, Katz AM, Abrams DN, Kalikhman D, Simon H, Woldeyohannes L, Zhang JY, et al. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent shank3 null mutant mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012; 32(19):6525–6541. [PubMed: 22573675]
36. Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, Walz C, Bolliger MF, Sudhof TC, Powell CM. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2010; 30(6):2115–2129. [PubMed: 20147539]
37. Etherton MR, Blaiss CA, Powell CM, Sudhof TC. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106(42):17998–18003. [PubMed: 19822762]
38. Portmann T, Yang M, Mao R, Panagiotakos G, Ellegood J, Dolen G, Bader PL, Grueter BA, Goold C, Fisher E, Clifford K, et al. Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome. *Cell reports*. 2014; 7(4):1077–1092. [PubMed: 24794428]
39. Muehlmann AM, Edington G, Mihalik AC, Buchwald Z, Koppuzha D, Korah M, Lewis MH. Further characterization of repetitive behavior in c58 mice: Developmental trajectory and effects of environmental enrichment. *Behavioural brain research*. 2012; 235(2):143–149. [PubMed: 22963990]
40. Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM, Baker S, Crawley JN. Gabab receptor agonist r-baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism. *Neuropsychopharmacology*. 2015; 40(9):2228–2239. [PubMed: 25754761]
41. Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, Ring RH, Crawley JN. Negative allosteric modulation of the mglur5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. *Science translational medicine*. 2012; 4(131):131ra151.
42. Bechard AR, Bliznyuk N, Lewis MH. The development of repetitive motor behaviors in deer mice: Effects of environmental enrichment, repeated testing, and differential mediation by indirect basal ganglia pathway activation. *Dev Psychobiol*. 2017; 59(3):390–399. [PubMed: 28181216]
43. Lewis MH, Tanimura Y, Lee LW, Bodfish JW. Animal models of restricted repetitive behavior in autism. *Behavioural brain research*. 2007; 176(1):66–74. [PubMed: 16997392]
44. Penagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A, Dong H, Sonnenblick LI, Gruver R, Almajano J, Bragin A, Golshani P, et al. Absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. *Cell*. 2011; 147(1):235–246. [PubMed: 21962519]
45. Spencer CM, Alekseyenko O, Hamilton SM, Thomas AM, Serysheva E, Yuva-Paylor LA, Paylor R. Modifying behavioral phenotypes in fmr1ko mice: Genetic background differences reveal autistic-like responses. *Autism research : official journal of the International Society for Autism Research*. 2011; 4(1):40–56. [PubMed: 21268289]

46. Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, Paylor R. Exaggerated behavioral phenotypes in *fmr1/fxr2* double knockout mice reveal a functional genetic interaction between fragile x-related proteins. *Human molecular genetics*. 2006; 15(12):1984–1994. [PubMed: 16675531]
47. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a *tsc2* mouse model of tuberous sclerosis. *Nat Med*. 2008; 14(8):843–848. [PubMed: 18568033]
48. Moy SS, Nadler JJ, Young NB, Perez A, Holloway LP, Barbaro RP, Barbaro JR, Wilson LM, Threadgill DW, Lauder JM, Magnuson TR, et al. Mouse behavioral tasks relevant to autism: Phenotypes of 10 inbred strains. *Behavioural brain research*. 2007; 176(1):4–20. [PubMed: 16971002]
49. Yang M, Silverman JL, Crawley JN. Automated three-chambered social approach task for mice. *Curr Protoc Neurosci*. 2011 Chapter 8(Unit 8 26).
50. Terranova ML, Laviola G. Scoring of social interactions and play in mice during adolescence. *Curr Protoc Toxicol*. 2005 Chapter 13(Unit 13 10).
51. Bales KL, Solomon M, Jacob S, Crawley JN, Silverman JL, Larke RH, Sahagun E, Puhger KR, Pride MC, Mendoza SP. Long-term exposure to intranasal oxytocin in a mouse autism model. *Transl Psychiatry*. 2014; 4:e480. [PubMed: 25386957]
52. Scattoni ML, McFarlane HG, Zhodzishsky V, Caldwell HK, Young WS, Ricceri L, Crawley JN. Reduced ultrasonic vocalizations in vasopressin 1b knockout mice. *Behavioural brain research*. 2008; 187(2):371–378. [PubMed: 18005969]
53. Scattoni ML, Crawley J, Ricceri L. Ultrasonic vocalizations: A tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. *Neurosci Biobehav Rev*. 2009; 33(4):508–515. [PubMed: 18771687]
54. Wöhr M, Silverman JL, Scattoni ML, Turner SM, Harris MJ, Saxena R, Crawley JN. Developmental delays and reduced pup ultrasonic vocalizations but normal sociability in mice lacking the postsynaptic cell adhesion protein neuroligin2. *Behav Brain Res*. 2013; 251:50–64. [PubMed: 22820233]
55. Copping NA, Christian SGB, Ritter DJ, Islam MS, Buscher N, Zolkowska D, Pride MC, Berg EL, LaSalle JM, Ellegood J, Lerch JP, et al. Neuronal overexpression of ube3a isoform 2 causes behavioral impairments and neuroanatomical pathology relevant to 15q11.2-q13.3 duplication syndrome. *Human molecular genetics*. 2017; 26(20):3995–4010. [PubMed: 29016856]
56. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. *Nature genetics*. 2000; 25(3):284–288. [PubMed: 10888874]
57. Ferguson JN, Aldag JM, Insel TR, Young LJ. Oxytocin in the medial amygdala is essential for social recognition in the mouse. *J Neurosci*. 2001; 21(20):8278–8285. [PubMed: 11588199]
58. Lee HJ, Caldwell HK, Macbeth AH, Young WS 3rd. Behavioural studies using temporal and spatial inactivation of the oxytocin receptor. *Prog Brain Res*. 2008; 170:73–77. [PubMed: 18655873]
59. Lee HJ, Caldwell HK, Macbeth AH, Tolu SG, Young WS 3rd. A conditional knockout mouse line of the oxytocin receptor. *Endocrinology*. 2008; 149(7):3256–3263. [PubMed: 18356275]
60. Macbeth AH, Edds JS, Young WS 3rd. Housing conditions and stimulus females: A robust social discrimination task for studying male rodent social recognition. *Nature protocols*. 2009; 4(11):1574–1581. [PubMed: 19816420]
61. Pearson BL, Bettis JK, Meyza KZ, Yamamoto LY, Blanchard DC, Blanchard RJ. Absence of social conditioned place preference in *btbr t+tf/j* mice: Relevance for social motivation testing in rodent models of autism. *Behavioural brain research*. 2012; 233(1):99–104. [PubMed: 22562042]
62. Brunner D, Kabitzke P, He D, Cox K, Thiede L, Hanania T, Sabath E, Alexandrov V, Saxe M, Peles E, Mills A, et al. Comprehensive analysis of the 16p11.2 deletion and null *cntnap2* mouse models of autism spectrum disorder. *PloS one*. 2015; 10(8):e0134572. [PubMed: 26273832]
63. Chadman KK, Gong S, Scattoni ML, Boltuck SE, Gandhi SU, Heintz N, Crawley JN. Minimal aberrant behavioral phenotypes of neuroligin-3 r451c knockin mice. *Autism research : official journal of the International Society for Autism Research*. 2008; 1(3):147–158. [PubMed: 19360662]

64. Tabuchi K, Blundell J, Etherton MR, Hammer RE, Liu X, Powell CM, Sudhof TC. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. *Science*. 2007; 318(5847):71–76. [PubMed: 17823315]
65. Ey E, Yang M, Katz AM, Woldeyohannes L, Silverman JL, Leblond CS, Faure P, Torquet N, Le Sourd AM, Bourgeron T, Crawley JN. Absence of deficits in social behaviors and ultrasonic vocalizations in later generations of mice lacking neuroligin4. *Genes Brain Behav*. 2012; 11(8): 928–941. [PubMed: 22989184]
66. Hill-Yardin EL, Argyropoulos A, Hosie S, Rind G, Anderson P, Hannan AJ, O'Brien TJ. Reduced susceptibility to induced seizures in the neuroligin-3(r451c) mouse model of autism. *Neurosci Lett*. 2015; 589:57–61. [PubMed: 25592157]
67. Jamain S, Radyushkin K, Hammerschmidt K, Granon S, Boretius S, Varoqueaux F, Ramanantsoa N, Gallego J, Ronnenberg A, Winter D, Frahm J, et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105(5):1710–1715. [PubMed: 18227507]
68. Kazdoba TM, Leach PT, Yang M, Silverman JL, Solomon M, Crawley JN. Translational mouse models of autism: Advancing toward pharmacological therapeutics. *Curr Top Behav Neurosci*. 2016
69. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: Interactions with laboratory environment. *Science*. 1999; 284(5420):1670–1672. [PubMed: 10356397]
70. Wahlsten D, Metten P, Phillips TJ, Boehm SL 2nd, Burkhart-Kasch S, Dorow J, Doerksen S, Downing C, Fogarty J, Rodd-Henricks K, Hen R, et al. Different data from different labs: Lessons from studies of gene-environment interaction. *J Neurobiol*. 2003; 54(1):283–311. [PubMed: 12486710]
71. Ey E, Yang M, Katz AM, Woldeyohannes L, Silverman JL, Leblond CS, Faure P, Torquet N, Le Sourd AM, Bourgeron T, Crawley JN. Absence of deficits in social behaviors and ultrasonic vocalizations in later generations of mice lacking neuroligin4. *Genes Brain Behav*. 2012; 11(8): 928–941. [PubMed: 22989184]
72. Blundell J, Tabuchi K, Bolliger MF, Blaiss CA, Brose N, Liu X, Sudhof TC, Powell CM. Increased anxiety-like behavior in mice lacking the inhibitory synapse cell adhesion molecule neuroligin 2. *Genes Brain Behav*. 2009; 8(1):114–126. [PubMed: 19016888]
73. Kabitzke P, Brunner D, He D, Fazio PA, Cox K, Sutphen J, Thiede L, Sabath E, Hanania T, Alexandrov V, Rasmuson R, et al. Comprehensive analysis of two shank3 and the cacna1c mouse models of autism spectrum disorder. *Genes Brain Behav*. 2017
74. Brigman JL, Daut RA, Saksida L, Bussey TJ, Nakazawa K, Holmes A. Impaired discrimination learning in interneuronal nmdar-glun2b mutant mice. *Neuroreport*. 2015; 26(9):489–494. [PubMed: 25968910]
75. Kazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile x syndrome in the fmr1 knockout mouse. *Intractable & rare diseases research*. 2014; 3(4):118–133. [PubMed: 25606362]
76. Pietropaolo S, Guilleminot A, Martin B, D'Amato FR, Crusio WE. Genetic-background modulation of core and variable autistic-like symptoms in fmr1 knock-out mice. *PloS one*. 2011; 6(2):e17073. [PubMed: 21364941]
77. Uutela M, Lindholm J, Louhivuori V, Wei H, Louhivuori LM, Pertovaara A, Akerman K, Castren E, Castren ML. Reduction of bdnf expression in fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits. *Genes Brain Behav*. 2012; 11(5):513–523. [PubMed: 22435671]
78. Henkelman RM. Systems biology through mouse imaging centers: Experience and new directions. *Annu Rev Biomed Eng*. 2010; 12:143–166. [PubMed: 20415591]
79. Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N, Kajiwar Y, Yang M, Katz AM, Scattoni ML, Harris MJ, et al. Haploinsufficiency of the autism-associated shank3 gene leads to deficits in synaptic function, social interaction, and social communication. *Molecular autism*. 2010; 1(1):15. [PubMed: 21167025]
80. Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, Greenough WT. Abnormal dendritic spines in fragile x knockout mice: Maturation and pruning deficits. *Proceedings of the*

- National Academy of Sciences of the United States of America. 1997; 94(10):5401–5404. [PubMed: 9144249]
81. Irwin SA, Galvez R, Greenough WT. Dendritic spine structural anomalies in fragile-x mental retardation syndrome. *Cerebral cortex*. 2000; 10(10):1038–1044. [PubMed: 11007554]
 82. Harlow EG, Till SM, Russell TA, Wijetunge LS, Kind P, Contractor A. Critical period plasticity is disrupted in the barrel cortex of *fmr1* knockout mice. *Neuron*. 2010; 65(3):385–398. [PubMed: 20159451]
 83. Nieman BJ, Flenniken AM, Adamson SL, Henkelman RM, Sled JG. Anatomical phenotyping in the brain and skull of a mutant mouse by magnetic resonance imaging and computed tomography. *Physiol Genomics*. 2006; 24(2):154–162. [PubMed: 16410543]
 84. Wong MD, Dorr AE, Walls JR, Lerch JP, Henkelman RM. A novel 3d mouse embryo atlas based on micro-ct. *Development*. 2012; 139(17):3248–3256. [PubMed: 22872090]
 85. Yang Y, Tai YC, Siegel S, Newport DF, Bai B, Li Q, Leahy RM, Cherry SR. Optimization and performance evaluation of the micropet ii scanner for in vivo small animal imaging. *Phys Med Biol*. 2004; 49(12):2527–2545. [PubMed: 15272672]
 86. Nieman BJ, Bock NA, Bishop J, Chen XJ, Sled JG, Rossant J, Henkelman RM. Magnetic resonance imaging for detection and analysis of mouse phenotypes. *NMR Biomed*. 2005; 18(7):447–468. [PubMed: 16206127]
 87. Nieman BJ, Bock NA, Bishop J, Sled JG, Josette Chen X, Mark Henkelman R. Fast spin-echo for multiple mouse magnetic resonance phenotyping. *Magn Reson Med*. 2005; 54(3):532–537. [PubMed: 16086298]
 88. Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. *Trends Neurosci*. 2008; 31(3):137–145. [PubMed: 18258309]
 89. Nordahl CW, Dierker D, Mostafavi I, Schumann CM, Rivera SM, Amaral DG, Van Essen DC. Cortical folding abnormalities in autism revealed by surface-based morphometry. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2007; 27(43):11725–11735. [PubMed: 17959814]
 90. Nordahl CW, Lange N, Li DD, Barnett LA, Lee A, Buonocore MH, Simon TJ, Rogers S, Ozonoff S, Amaral DG. Brain enlargement is associated with regression in preschool-age boys with autism spectrum disorders. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108(50):20195–20200. [PubMed: 22123952]
 91. Ohta H, Nordahl CW, Iosif AM, Lee A, Rogers S, Amaral DG. Increased surface area, but not cortical thickness, in a subset of young boys with autism spectrum disorder. *Autism research : official journal of the International Society for Autism Research*. 2015
 92. Shen MD, Kim SH, McKinstry RC, Gu H, Hazlett HC, Nordahl CW, Emerson RW, Shaw D, Elison JT, Swanson MR, Fonov VS, et al. Increased extra-axial cerebrospinal fluid in high-risk infants who later develop autism. *Biol Psychiatry*. 2017; 82(3):186–193. [PubMed: 28392081]
 93. Sussman D, Leung RC, Vogan VM, Lee W, Trelle S, Lin S, Cassel DB, Chakravarty MM, Lerch JP, Anagnostou E, Taylor MJ. The autism puzzle: Diffuse but not pervasive neuroanatomical abnormalities in children with asd. *Neuroimage Clin*. 2015; 8:170–179. [PubMed: 26106541]
 94. Leonard CM, Williams CA, Nicholls RD, Agee OF, Voeller KK, Honeyman JC, Staab EV. Angelman and prader-willi syndrome: A magnetic resonance imaging study of differences in cerebral structure. *American journal of medical genetics*. 1993; 46(1):26–33. [PubMed: 8494031]
 95. Miller JL, Couch JA, Schmalfuss I, He G, Liu Y, Driscoll DJ. Intracranial abnormalities detected by three-dimensional magnetic resonance imaging in prader-willi syndrome. *American journal of medical genetics Part A*. 2007; 143A(5):476–483. [PubMed: 17103438]
 96. Rice LJ, Lagopoulos J, Brammer M, Einfeld SL. Microstructural white matter tract alteration in prader-willi syndrome: A diffusion tensor imaging study. *Am J Med Genet C Semin Med Genet*. 2017; 175(3):362–367. [PubMed: 28834083]
 97. Yamada K, Matsuzawa H, Uchiyama M, Kwee IL, Nakada T. Brain developmental abnormalities in prader-willi syndrome detected by diffusion tensor imaging. *Pediatrics*. 2006; 118(2):e442–448. [PubMed: 16882785]
 98. Lerch JP, Sled JG, Henkelman RM. Mri phenotyping of genetically altered mice. *Methods Mol Biol*. 2011; 711:349–361. [PubMed: 21279611]

99. Ellegood J, Anagnostou E, Babineau BA, Crawley JN, Lin L, Genestine M, DiCicco-Bloom E, Lai JK, Foster JA, Penagarikano O, Geschwind DH, et al. Clustering autism: Using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. *Molecular psychiatry*. 2015; 20(1):118–125. [PubMed: 25199916]
100. Ellegood J, Babineau BA, Henkelman RM, Lerch JP, Crawley JN. Neuroanatomical analysis of the btbr mouse model of autism using magnetic resonance imaging and diffusion tensor imaging. *Neuroimage*. 2013; 70:288–300. [PubMed: 23275046]
101. Ellegood J, Henkelman RM, Lerch JP. Neuroanatomical assessment of the integrin beta3 mouse model related to autism and the serotonin system using high resolution mri. *Front Psychiatry*. 2012; 3(37)
102. Portmann T, Yang M, Mao R, Panagiotakos G, Ellegood J, Dolen G, Bader PL, Grueter BA, Goold C, Fisher E, Clifford K, et al. Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome. *Cell Rep*. 2014; 7(4):1077–1092. [PubMed: 24794428]
103. Allemang-Grand R, Ellegood J, Spencer Noakes L, Ruston J, Justice M, Nieman BJ, Lerch JP. Neuroanatomy in mouse models of rett syndrome is related to the severity of mecp2 mutation and behavioral phenotypes. *Molecular autism*. 2017; 8(32)
104. Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. *Neuron*. 2006; 51(5):527–539. [PubMed: 16950152]
105. Bock NA, Nieman BJ, Bishop JB, Mark Henkelman R. In vivo multiple-mouse mri at 7 tesla. *Magn Reson Med*. 2005; 54(5):1311–1316. [PubMed: 16215960]
106. Kumar A, Wadhawan R, Swanwick CC, Kollu R, Basu SN, Banerjee-Basu S. Animal model integration to autdb, a genetic database for autism. *BMC Med Genomics*. 2011; 4(15)
107. Banerjee-Basu S, Packer A. Sfari gene: An evolving database for the autism research community. *Dis Model Mech*. 2010; 3(3–4):133–135. [PubMed: 20212079]
108. Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, Witherspoon K, Gerdts J, Baker C, Vulto-van Silfhout AT, Schuurs-Hoeijmakers JH, et al. Disruptive chd8 mutations define a subtype of autism early in development. *Cell*. 2014; 158(2):263–276. [PubMed: 24998929]
109. Kimura H, Wang C, Ishizuka K, Xing J, Takasaki Y, Kushima I, Aleksic B, Uno Y, Okada T, Ikeda M, Mori D, et al. Identification of a rare variant in chd8 that contributes to schizophrenia and autism spectrum disorder susceptibility. *Schizophrenia research*. 2016; 178(1–3):104–106. [PubMed: 27595554]
110. Merner N, Forgeot d'Arc B, Bell SC, Maussion G, Peng H, Gauthier J, Crapper L, Hamdan FF, Michaud JL, Mottron L, Rouleau GA, et al. A de novo frameshift mutation in chromodomain helicase DNA-binding domain 8 (chd8): A case report and literature review. *Am J Med Genet A*. 2016; 170A(5):1225–1235. [PubMed: 26789910]
111. Stolerman ES, Smith B, Chaubey A, Jones JR. Chd8 intragenic deletion associated with autism spectrum disorder. *Eur J Med Genet*. 2016; 59(4):189–194. [PubMed: 26921529]

Key Bullet Points

- Next generation technology has generated an abundance of precise novel genetic mouse models that are essential for research on neurodevelopmental disorders (NDD).
- Translational outcome measures, such as behavior and brain anatomy, are leading numerous discoveries of the underlying NDD neurobiology via the new mouse models.
- Behavioral domains core to NDD are complex and require multiple assays for accurate interpretation.
- Linking behavioral outcomes with neuroanatomical metrics will inform mechanistic hypotheses and therapeutic targets.
- Systems level approaches will be heavily relied upon for therapeutic development, as biological markers and outcome measures.